Shionogi & Co Ltd – Market Analysis Product Pipeline Review – 2016

 HTF Market Intelligence released a new research report of 88 pages on title ‘Shionogi & Co Ltd – Product Pipeline Review – 2016’  with detailed analysis, forecast and strategies.


Shionogi & Co Ltd – Product Pipeline Review – 2016

Global Markets Direct’s, ‘Shionogi & Co Ltd – Product Pipeline Review – 2016’, provides an overview of the Shionogi & Co Ltd’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Shionogi & Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


– The report provides a snapshot of the pipeline therapeutic landscape of Shionogi & Co Ltd

– The report provides overview of Shionogi & Co Ltd including its business description, key facts, and locations and subsidiaries

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report assesses Shionogi & Co Ltd’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report features Shionogi & Co Ltd’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

– Evaluate Shionogi & Co Ltd’s strategic position with total access to detailed information on its product pipeline

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand important and diverse types of therapeutics under development for Shionogi & Co Ltd

– Identify potential new clients or partners in the target demographic

– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Shionogi & Co Ltd’s pipeline depth and focus of pipeline therapeutics

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Make an enquiry before buying this Report @

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Shionogi & Co Ltd Snapshot 9

Shionogi & Co Ltd Overview 9

Key Facts 9

Shionogi & Co Ltd – Research and Development Overview 10

Key Therapeutic Areas 10

Shionogi & Co Ltd – Pipeline Review 14

Pipeline Products by Stage of Development 14

Pipeline Products – Monotherapy 15

Pipeline Products – Combination Treatment Modalities 16

Pipeline Products – Partnered Products 17

Partnered Products/Combination Treatment Modalities 18

Pipeline Products – Out-Licensed Products 19

Out-Licensed Products/Combination Treatment Modalities 20

Shionogi & Co Ltd – Pipeline Products Glance 21

Shionogi & Co Ltd – Late Stage Pipeline Products 21

Pre-Registration Products/Combination Treatment Modalities 21

Phase III Products/Combination Treatment Modalities 22

Shionogi & Co Ltd – Clinical Stage Pipeline Products 23

Phase II Products/Combination Treatment Modalities 23

Phase I Products/Combination Treatment Modalities 24

Shionogi & Co Ltd – Early Stage Pipeline Products 25

Preclinical Products/Combination Treatment Modalities 25

Discovery Products/Combination Treatment Modalities 26

Shionogi & Co Ltd – Drug Profiles 27

A-2NTX – Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

AMG-0101 – Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

asapiprant – Drug Profile 31

Product Descrip

Read Detailed Table of Content @

Buy this report @

Contact Us:

CRAIG FRANCIS (PR & Marketing Manager)

Ph: +1 (206) 317 1218

%d bloggers like this: